Issue Contents

Basic Mechanisms of JAK Inhibition

Chung MA Lin, Faye AH Cooles, John D. Isaacs

Mediterr J Rheumatol 2020;31(Supp 1):100-4
Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

George Bertsias

Mediterr J Rheumatol 2020;31(Supp 1):105-11
Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?

Puja Mehta, Peter C. Taylor

Mediterr J Rheumatol 2020;31(Supp 1):112-9
Beyond Methotrexate and Biologics in RA – Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium

Katerina Chatzidionysiou

Mediterr J Rheumatol 2020;31(Supp 1):120-8
Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

Konstantinos Thomas, Dimitrios Vassilopoulos

Mediterr J Rheumatol 2020;31(Supp 1):129-36
Under Development JAK Inhibitors for Dermatologic Diseases

Nikolaos Sideris, Efstratios Vakirlis, Aikaterini Tsentemeidou, Alexandra Kourouklidou, Demetrios Ioannides, Elena Sotiriou

Mediterr J Rheumatol 2020;31(Supp 1):137-44
Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists

Theofilos-Diamantis Karatsourakis, Xenofon Baraliakos

Mediterr J Rheumatol 2020;31(Supp 1):145-51
Patients’ and Doctors’ Beliefs about Treatment and Long-Term Adherence in Rheumatic Diseases

John Yfantopoulos, Marianna Protopapa, Konstantinos Mantalias, Athanasios Chantzaras, Katerina Koutsogianni, Platonas Yfantopoulos, Dimitrios Vassilopoulos

Mediterr J Rheumatol 2020;31(Supp 1):152-62
Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis

Dimitrios Vassilopoulos, Spiros Aslanidis, Dimitrios Boumpas, George Kitas, Spyridon N. Nikas, Dimos Patrikos, Petros P. Sfikakis, Prodromos Sidiropoulos

Mediterr J Rheumatol 2020;31(Supp 1):163-71

ARCHIVE

Volume 31, Issue 2, June 2020 - Supplement 1